One year on, J&J's Synthes buy finally gets EU green light
This article was originally published in Clinica
Executive Summary
The finishing line is now in sight for Johnson & Johnson's planned billion-dollar acquisition of trauma specialist Synthes, after European anti-trust regulators finally approved the takeover. J&J agreed to buy Synthes for €19bn nearly a year ago ($21.3bn based on the exchange rate at that time) in a deal that would strengthen its leading position in the global orthopaedics market and catapulting it to the number-one spot in the $5.5bn trauma device market (www.clinica.co.uk, 27 April 2011).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.